Propofol infusion syndrome: A structured review of experimental studies and 153 published case reports

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Krajčová, Adéla ^a   Waldauf, Petr ^a   Anděl, Michal ^a   Duška, František ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROPOFOL; INTRAVENOUS ANESTHETIC AGENT;

ABNORMAL URINE COMPOSITION; ACUTE KIDNEY FAILURE; ANESTHESIA COMPLICATION; ARTICLE; DOSE RESPONSE; ECG ABNORMALITY; FATTY LIVER; FEVER; HEART ARRHYTHMIA; HEART FAILURE; HEPATOMEGALY; HUMAN; HYPERKALEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INFUSION RATE; INTENSIVE CARE; LIVER DYSFUNCTION; LUNG EDEMA; METABOLIC ACIDOSIS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROPOFOL INFUSION SYNDROME; RHABDOMYOLYSIS; SEDATION; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; URINE DISCOLORATION; CHEMICALLY INDUCED; RISK FACTOR; SYNDROME;

ANESTHETICS, INTRAVENOUS; ARRHYTHMIAS, CARDIAC; FEVER; HEART FAILURE; HEPATOMEGALY; HUMANS; HYPERTRIGLYCERIDEMIA; MORTALITY; PROPOFOL; RISK FACTORS; SYNDROME;

EID: 84946739383     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-1112-5     Document Type: Article

References (63)

1. Tiwari R. U.S. Anesthesia Drugs Market Worth $3 Billion + by 2018. http://www.prnewswire.com/news-releases/us-anesthesia-drugs-market-worth--3-billion-by-2018-285487841.html. Accessed 6 May 2015.
2. Global market study on propofol. http://www.aranca.com/downloads/case-studies/business-research/vertical-expertise/global-market-study-on-propofol-2-pharma-and-medical-devices-br-case-study.pdf. Accessed 6 May 2015.
3. Lonardo NW, Mone MC, Nirula R, Kimball EJ, Ludwig K, Zhou X, et al. Propofol is associated with favorable outcomes compared with benzodiazepines in ventilated intensive care unit patients. Am J Respir Crit Care Med. 2014;189(11):1383-94.
4. Fraser GL, Devlin JW, Worby CP, Alhazzani W, Barr J, Dasta JF, et al. Benzodiazepine versus nonbenzodiazepine-based sedation for mechanically ventilated, critically ill adults: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2013;41(9 Suppl 1):S30-8.
5. Notis fra Bivirkningsnaenet. Propofol (Diprivan) bivirkninger. [Adverse effects of propofol (Diprivan)]. Ugeskr Laeger. 1990;152(16):1176.
6. Parke TJ, Stevens JE, Rice AS, Greenaway CL, Bray RJ, Smith PJ, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ. 1992;305(6854):613-6.
7. Bodd E, Endresen L. Use of propofol for children. Tidsskr Nor Laegeforen. 1992;112:1636-7.
8. Kirkpatrick M, Cole G. Propofol infusion in children. BMJ. 1992;305(6863):1223.
9. Barclay K, Williams AJ, Major E. Propofol infusion in children. BMJ. 1992;305(6859):953. author reply 953-4.
10. Bray RJ. Fatal myocardial failure associated with a propofol infusion in a child. Anaesthesia. 1995;50(1):94.
11. Strickland RA, Murray MJ. Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: is there a relationship? Crit Care Med. 1995;23(2):405-9.
12. Marinella MA. Lactic acidosis associated with propofol. Chest. 1996;109(1):292.
13. Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology. 1998;50(1):301-3.
14. Perrier ND, Baerga-Varela Y, Murray MJ. Death related to propofol use in an adult patient. Crit Care Med. 2000;28(8):3071-4.
15. Stelow EB, Johari VP, Smith SA, Crosson JT, Apple FS. Propofol-associated rhabdomyolysis with cardiac involvement in adults: chemical and anatomic findings. Clin Chem. 2000;46(4):577-81.
16. Cremer OL, Moons KG, Bouman EA, Kruijswijk JE, de Smet AM, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet. 2001;357(9250):117-8.
17. U.S. Food and Drug Administration MedWatch. 2001 safety alerts for drugs, biologics, medical devices, and dietary supplements. Diprivan (propofol). http://www.fda.gov/medwaTCH/SAFETY/2001/safety01.htm#diprivan%5D. Accessed 23 Dec 2014.
18. U.S. Food and Drug Administration. MedWatch. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER)-February 2007. Diprivan (propofol) injectable emulsion for IV administration. http://www.fda.gov/Medwatch/SAFETY/2007/feb07.htm#Diprivan. Accessed 23 Dec 2014.
19. Ahlen K, Buckley CJ, Goodale DB, Pulsford AH. The 'propofol infusion syndrome': the facts, their interpretation and implications for patient care. Eur J Anaesthesiol. 2006;23(12):990-8.
20. Summary of Product Characteristics: PROPOFOL. https://www.medicines.org.uk/emc/medicine/2275#UNDESIRABLE_EFFECTS. Accessed 6 May 2015.
21. European Medicines Agency. European database of suspected drug reaction reports. https://bi.ema.europa.eu/analyticsSOAP/saw.dll?PortalPages. Accessed 6 May 2015.
22. Bray RJ. Propofol infusion syndrome in children. Pediatr Anesth. 1998;8(6):491-9.
23. Chukwuemeka A, Ko R, Ralph-Edwards A. Short-term low-dose propofol anaesthesia associated with severe metabolic acidosis. Anaesth Intensive Care. 2006;34(5):651-5.
24. Roberts RJ, Barletta JF, Fong JJ, Schumaker G, Kuper PJ, Papadopoulos S, et al. Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study. Crit Care. 2009;13(5):R169.
25. Richter S, Brugada P. Propofol-induced coved-type electrocardiogram during catheter ablation of paroxysmal atrial fibrillation. A case of Brugada syndrome? Herzschrittmacherther Elektrophysiol. 2012;23(1):56-8.
26. Schroeppel TJ, Fabian TC, Clement LP, Fischer PE, Magnotti LJ, Sharpe JP, et al. Propofol infusion syndrome: a lethal condition in critically injured patients eliminated by a simple screening protocol. Injury. 2014;45(1):245-9.
27. Linko R, Laukkanen A, Koljonen V, Rapola J, Varpula T. Severe heart failure and rhabdomyolysis associated with propofol infusion in a burn patient. J Burn Care Res. 2014;35(5):e364-7.
28. Rottenberg H. Uncoupling of oxidative phosphorylation in rat liver mitochondria by general anesthetics. Proc Natl Acad Sci U S A. 1983;80(11):3313-7.
29. Branca D, Roberti MS, Lorenzin P, Vincenti E, Scutari G. Influence of the anesthetic 2,6-diisopropylphenol on the oxidative phosphorylation of isolated rat liver mitochondria. Biochem Pharmacol. 1991;42(1):87-90.
30. Branca D, Roberti MS, Vincenti E, Scutari G. Uncoupling effect of the general anesthetic 2,6-diisopropylphenol in isolated rat liver mitochondria. Arch Biochem Biophys. 1991;290(2):517-21.
31. Rigoulet M, Devin A, Avéret N, Vandais B, Guérin B. Mechanisms of inhibition and uncoupling of respiration in isolated rat liver mitochondria by the general anesthetic 2,6-diisopropylphenol. Eur J Biochem. 1996;241(1):280-5.
32. Branca D, Vincenti E, Scutari G. Influence of the anesthetic 2,6-diisopropylphenol (propofol) on isolated rat heart mitochondria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1995;110(1):41-5.
33. Schenkman KA, Yan S. Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. Crit Care Med. 2000;28(1):172-7.
34. Mehta N, DeMunter C, Habibi P, Nadel S, Britto J. Short-term propofol infusions in children. Lancet. 1999;354(9181):866-7.
35. Cray SH, Robinson BH, Cox PN. Lactic acidemia and bradyarrhythmia in a child sedated with propofol. Crit Care Med. 1998;26:2087-92.
36. Vanlander AV, Okun JG, de Jaeger A, Smet J, De Latter E, De Paepe B, et al. Possible pathogenic mechanism of propofol infusion syndrome involves coenzyme Q. Anesthesiology. 2015;122(2):343-52.
37. Wolf A, Weir P, Segar P, Stone J, Shield J. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet. 2001;357(9256):606-7.
38. Wolf AR, Potter F. Propofol infusion in children: when does an anesthetic tool become an intensive care liability? Paediatr Anaesth. 2004;14(6):435-8.
39. Withington DE, Decell MK, Al AT. A case of propofol toxicity: further evidence for a causal mechanism. Paediatr Anaesth. 2004;14(6):505-8.
40. Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. http://www.nature.com/gim/journal/v10/n2/pdf/gim200822a.pdf. Accessed 6 May 2015.
41. Baumeister FA, Oberhoffer R, Liebhaber GM, Kunkel J, Eberhardt J, Holthausen H, et al. Fatal propofol infusion syndrome in association with ketogenic diet. Neuropediatrics. 2004;35(4):250-2.
42. Cree MG, Wolfe RR. Postburn trauma insulin resistance and fat metabolism. Am J Physiol Endocrinol Metab. 2008;294(1):E1-9.
43. Tong XX, Kang Y, Liu FZ, Zhang WS, Liu J. Effect of prolonged infusion of propofol on the liver mitochondria respiratory function in rabbits. Sichuan Da Xue Xue Bao Yi Xue Ban. 2010;41(6):1021-3.
44. Lee SK, Lee JO, Kim JH, Kim N, You GY, Moon JW, et al. Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated PPARaα induction in 3T3-L1 preadipocytes. Cell Signal. 2012;24(12):2329-36.
45. Jiang W, Yang ZB, Zhou QH, Huan X, Wang L. Lipid metabolism disturbances and AMPK activation in prolonged propofol-sedated rabbits under mechanical ventilation. Acta Pharmacol Sin. 2012;33(1):27-33.
46. Lin MC, Chen CL, Yang TT, Choi PC, Hsing CH, Lin CF. Anesthetic propofol overdose causes endothelial cytotoxicity in vitro and endothelial barrier dysfunction in vivo. Toxicol Appl Pharmacol. 2012;265(2):253-62.
47. Kill C, Leonhardt A, Wulf H. Lacticacidosis after short-term infusion of propofol for anaesthesia in a child with osteogenesis imperfecta. Paediatr Anaesth. 2003;13(9):823-6.
48. Koch M, De Backer D, Vincent JL. Lactic acidosis: an early marker of propofol infusion syndrome? Intensive Care Med. 2004;30(3):522.
49. Holzki J, Aring C, Gillor A. Death after re-exposure to propofol in a 3-year-old child: a case report. Paediatr Anaesth. 2004;14(3):265-70.
50. Romero PC, Morales RM, Donaire RL, Llanos VO, Cornejo RR, Gálvez AR, et al. Severe lactic acidosis caused by propofol infusion: report of one case. Rev Med Chil. 2008;136(1):88-92.
51. Burow BK, Johnson ME, Packer DL. Metabolic acidosis associated with propofol in the absence of other causative factors. Anesthesiology. 2004;101(1):239-41.
52. Haase R, Sauer H, Eichler G. Lactic acidosis following short-term propofol infusion may be an early warning of propofol infusion syndrome. J Neurosurg Anesthesiol. 2005;17(2):122-3.
53. Westhout FD, Muhonen MG, Nwagwu CI. Early propofol infusion syndrome following cerebral angiographic embolization for giant aneurysm repair. Case report. J Neurosurg. 2007;106(2 Suppl):139-42.
54. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med. 2007;356(11):1140-51.
55. Ypsilantis P, Politou M, Mikroulis D, Pitiakoudis M, Lambropoulou M, Tsigalou C, et al. Organ toxicity and mortality in propofol-sedated rabbits under prolonged mechanical ventilation. Anesth Analg. 2007;105(1):155-66.
56. Jouven X, Charles MA, Desnos M, Ducimetière P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation. 2001;104(7):756-61.
57. Stanley CA, Bennett MJ, Mayatepek E. Disorders of mitochondrial fatty acid oxidation and related metabolic pathways. In: Inborn metabolic diseases. Berlin: Springer Berlin Heidelberg; 2006. p. 175-90.
58. Terrone G, Ruoppolo M, Brunetti-Pierri N, Cozzolino C, Scolamiero E, Parenti G, et al. Child neurology: recurrent rhabdomyolysis due to a fatty acid oxidation disorder. Neurology. 2014;82(1):e1-4.
59. Heyman MB, Storch S, Ament ME. The fat overload syndrome. Report of a case and literature review. Am J Dis Child. 1981;135(7):628-30.
60. Adolph M, Heller AR, Koch T, Koletzko B, Kreymann KG, Krohn K, et al. Lipid emulsions-Guidelines on Parenteral Nutrition, Chapter 6. Ger Med Sci. 2009;7:Doc22.
61. Gura KM, Puder M. Rapid infusion of fish oil-based emulsion in infants does not appear to be associated with fat overload syndrome. Nutr Clin Pract. 2010;25(4):399-402.
62. Fong JJ, Sylvia L, Ruthazer R, Schumaker G, Kcomt M, Devlin JW. Predictors of mortality in patients with suspected propofol infusion syndrome. Crit Care Med. 2008;36(8):2281-7.
63. Commissioner OOT. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. http://www.fda.gov/Safety/MedWatch/. Accessed 6 May 2015.